Ipsen Sustainability Profile
Ipsen S.A., a global biopharmaceutical group headquartered in France, has established itself as a leader in the healthcare industry since its founding in 1929. With a strong presence in Europe, North America, and Asia, Ipsen focuses on innovative treatments in oncology, neuroscience, and rare diseases. The company is renowned for its core products, including Somatuline® and Cabometyx®, which are distinguished by their unique mechanisms of action and efficacy in treating complex conditions. Ipsen's commitment to research and development has led to significant milestones, including the expansion of its product portfolio and strategic partnerships that enhance its market position. Recognised for its dedication to patient care and innovation, Ipsen continues to make strides in the biopharmaceutical sector, contributing to advancements that improve the quality of life for patients worldwide.
DitchCarbon Score
How does Ipsen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ipsen's score of 82 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ipsen's reported carbon emissions
In 2024, Ipsen reported significant carbon emissions, with Scope 1 emissions totalling approximately 2,659,700 kg CO2e in France and 28,700 kg CO2e in the US. The company also disclosed Scope 2 emissions of about 2000 kg CO2e in the US, 5,600 kg CO2e in China, and 3,000 kg CO2e in Vietnam. Globally, Ipsen's total emissions included approximately 9,931,200 kg CO2e from Scope 1, 289,000 kg CO2e from Scope 2, and a substantial 90,705,000 kg CO2e from Scope 3. Ipsen has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 emissions by 50% by 2030 from a 2019 baseline. Additionally, the company targets a 20% reduction in Scope 3 emissions within the same timeframe. Looking further ahead, Ipsen is committed to achieving net-zero greenhouse gas emissions across all scopes by 2045, with a long-term goal of reducing emissions by at least 90% from 2019 levels. These targets align with the Science Based Targets initiative (SBTi) and reflect Ipsen's commitment to the Paris Agreement's goal of limiting global warming to 1.5°C. The company is currently on track to meet its near-term targets, demonstrating a proactive approach to climate action within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 14,316,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 2 | 4,343,000 | 0,000,000 | 0,000,000 | 000,000 | 000,000 |
| Scope 3 | 121,718,000 | 00,000,000 | 00,000,000 | - | 00,000,000 |
How Carbon Intensive is Ipsen's Industry?
How Carbon Intensive is Ipsen's Location?
Ipsen's Scope 3 Categories Breakdown
Ipsen's Scope 3 emissions, which increased by 405% last year and decreased by approximately 25% since 2019, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 67% of Scope 3 emissions.
Top Scope 3 Categories
Ipsen's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Ipsen has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Frequently Asked Questions
Common questions about Ipsen's sustainability data and climate commitments